REG - Imaging Biometrics - IB Announces Completion of Phase 1 Trial of GaM

Imaging BiometricsAnnouncement

10/11/2025 15:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251110:nRSJ9232Ga&default-theme=true

RNS Number : 9232G  Imaging Biometrics Limited  10 November 2025

Imaging Biometrics, Ltd

(the "Company")

 

Imaging Biometrics Announces Successful Completion of Phase 1 Trial of Gallium
Maltolate in Recurrent Glioblastoma

 

Imaging Biometrics, LLC, ("IB"), a leader in advanced quantitative imaging
solutions, today announces the successful completion of its Phase 1 clinical
trial evaluating oral gallium maltolate (GaM) for the treatment of recurrent
or relapsed glioblastoma (GBM) - a major milestone in the company's oncology
development program.

 

Following comprehensive internal reviews conducted by the Medical College of
Wisconsin (MCW), the trial met all predefined Phase 1 objectives, including
safety, tolerability, and pharmacokinetic benchmarks. Importantly, significant
adverse events were not observed, underscoring GaM's favorable safety profile.

 

"This achievement marks a pivotal step forward in our mission to bring novel,
mechanism-driven therapies to patients with GBM," said Trevor Brown, CEO of
Imaging Biometrics Ltd. "We are encouraged by the data and the continued
treatment of one long-standing patient, which speaks to GaM's potential
clinical benefit. We look forward to sharing the full summary analysis soon."

 

The trial, led by Dr. Jennifer Connelly, MD (Principal Investigator) and Dr.
Christopher Chitambar, MD (Co-Principal Investigator and Study Chair),
enrolled 26 patients in a dose-escalation design. Of these, 24 were evaluable
for toxicity, with 22 included in a preliminary efficacy assessment. All
patients tolerated GaM exceptionally well, with no reported toxicities.

 

Oral GaM is a novel therapeutic candidate that targets tumor metabolism and
iron-dependent cancer growth. Preclinical studies suggest its unique mechanism
of action may synergize with existing treatment modalities, offering a
promising new avenue for GBM therapy.

 

With Phase 1 now complete, IB is actively engaging with leading cancer centers
to initiate a Phase 2 trial aimed at further evaluating GaM's efficacy and
expanding its clinical footprint.

 

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

For further information, please contact:

 

 IB Ltd

 Trevor Brown/Dr Al Musella/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 AlbR Capital Limited (Broker)

 Tel: 020 7220 9797

 

About Imaging Biometrics® LLC:  IB is a wholly-owned subsidiary of Imaging
Biometrics Limited, (LON: IBAI), and focuses on delivering quantitative
imaging platforms and therapeutics that transform how clinicians diagnose and
treat patients more efficiently and effectively. For more information about
Imaging Biometrics, visit the company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com/) . Follow IB on X, @ImgBiometrics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STREBLFFEFLBFBK



            Copyright 2019 Regulatory News Service, all rights reserved